Impact of Allergic Rhinitis Control on Work Productivity and Costs: A Real-World Data MASK-air Study

Background

Allergic rhinitis (AR) has a substantial socioeconomic impact associated with impaired work productivity.

Objective

To study the impact of AR on work productivity and estimate the corresponding indirect costs for 40 countries.

Methods

We conducted a cross-sectional study using direct patient data from the MASK-air app on users with self-reported AR. We used the Work Productivity and Activity Impairment Questionnaire: Allergy Specific to measure the impact of AR on work productivity (presenteeism and absenteeism). Weekly indirect costs were estimated per country for each level of rhinitis control. Patients with and without asthma were considered.

Results

We assessed data from 677 weeks (364 patients), 280 of which were reported by patients with asthma. Regarding presenteeism, the median impact of AR in weeks of poor disease control was 60.7% (percentiles 25–75 [P25–P75] 24.9%–74.2%), whereas partial and good disease control were, respectively, associated with an impact of 25.0% (P25–P75 12.1%–42.4%) and 4.4% (P25–P75 0.8%–12.9%). In poorly controlled weeks, presenteeism was associated with indirect costs ranging from 65.7 US$ purchase power parities (PPPs) (P25–P75 29.2–143.2) in Brazil to 693.6 US$ PPP (P25–P75 405.2–1,094.9) in Iceland. Median absenteeism per week was of 0% for all levels of rhinitis control. Patients with AR + asthma showed higher overall work impairment than patients with AR alone, particularly in poorly controlled weeks (median work impairment in AR alone 39.1% [P25–P75 12.5%–71.9%]; median work impairment in AR + asthma 68.4% [P25–P75 54.6%–80.2%]).

Conclusions

Poor AR control was associated with decreased work productivity and increased indirect costs, particularly in patients with AR + asthma. The estimates from this study underpin the economic burden of AR.